BATS BZX Real-Time Price
As of 10:26am ET
| -0.12 / -0.15%|
The 18 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 67.00, with a high estimate of 116.00 and a low estimate of 42.00. The median estimate represents a -15.95% decrease from the last price of 79.71.
The current consensus among 19 polled investment analysts is to Hold stock in Alnylam Pharmaceuticals Inc. This rating has held steady since June, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.